Drug Profile
LDL receptor gene therapy - Copernicus Therapeutics
Latest Information Update: 25 Mar 2008
Price :
$50
*
At a glance
- Originator Copernicus Therapeutics
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 25 Mar 2008 Discontinued - Preclinical for Hypercholesterolaemia in USA (IV)
- 13 Jul 1999 New profile
- 13 Jul 1999 Preclinical development for Hypercholesterolaemia in USA (IV)